Case Acceptance & Treatment Conversion Intelligence

The $284,871 Opportunity

Case conversion is the single largest operational revenue opportunity in the average dental practice. The gap between the institutional target of 75% conversion and the 55% industry median represents $284,871 in annually recurring revenue — treatment that has already been diagnosed, already been presented, and is sitting in the patient base waiting to be scheduled.

This is not theoretical revenue. These are patients who sat in the chair, received a diagnosis, heard a treatment recommendation, and left without scheduling. Every one of them represents a specific dollar amount of identified, capturable production. The treatment has been mapped. The clinical need exists. The patient is aware. What's missing is the system to convert awareness into action.

For founders evaluating an exit within 24 months, case acceptance is the single highest-leverage operational improvement available — because the revenue is already in the building. No additional marketing spend, no new patient acquisition cost, no incremental chair time for diagnosis. The only investment is in the conversion system itself.

Case Conversion Benchmark

The institutional target is 75%+ of treatment dollars presented either completed or accepted.

Percentile Distribution

Percentile	Case Acceptance Rate
Top 10%	77%
Top 25%	62%
Top 50% (Median)	55%
Top 75%	44%
Top 90%	37%

Annual revenue opportunity: $284,871 — calculated from the treatment presentation delta across the full patient base. This is the single largest identified operational opportunity, exceeding even patient education ($179,234) and retention ($105,411).

The Measurement Trap

Most founders believe their case acceptance is 80%+ because they only measure the patients who say yes. Their practice management system reports "accepted treatment" as a percentage of treatment where the patient gave verbal or written consent. This number is comforting and misleading.

The institutional measurement is total dollars presented versus total dollars closed — including every patient who walked out without scheduling, every patient who said "let me think about it," every patient who accepted verbally but never booked. When measured against total presentation value including unscheduled treatment, the median practice is at 55%.

The delta between perceived and actual case acceptance is often the most uncomfortable data point in PDA's analysis. A practice owner who believes they're at 82% and discovers they're at 51% has a $300K+ annual revenue gap they didn't know existed. That gap is simultaneously the biggest vulnerability (it suppresses current EBITDA) and the biggest opportunity (it represents identified growth runway that a buyer can underwrite).

Third-Party Financing as the Conversion Lever

The operational data is unambiguous: practices with structured financing stacks outperform single-option practices on case acceptance by double-digit percentages.

The Optimized Financing Architecture

• Prime lender: CareCredit, LendingClub, or equivalent — 0% promotional financing for credit-qualified patients. This captures the "I want to do it but not all at once" segment.
• Sub-prime lender: A secondary financing partner that approves patients who don't qualify for prime lending. This captures the "I want to do it but I'm worried about approval" segment — a segment that most practices lose entirely.
• High-ticket option: For treatment plans exceeding $10K — orthodontics, full-arch, implant-supported prosthetics — a lending partner with extended terms (48-72 months) that makes the monthly payment psychologically manageable.

The Critical KPI

PDA tracks financing applications submitted, not just approvals. The bottleneck in most practices is not approval rates — modern dental lending approves 60-80% of applications across prime and sub-prime combined. The bottleneck is that the financial coordinator never presents the option. Practices with sub-6% financing utilization (applications submitted as a percentage of treatment presented over $500) have a structural conversion ceiling that no amount of clinical skill or chairside persuasion will overcome.

Activating a structured financing presentation — where every patient with treatment over $500 is offered financing as a standard part of the financial discussion, not as a last resort — is consistently the highest-ROI operational intervention PDA deploys.

Treatment Presentation Methodology

PDA deploys a structured case presentation framework that separates diagnosis from financial discussion and creates systematic follow-through on unaccepted treatment.

The principle is measurable: practices using structured presentation protocols achieve higher per-case value and higher acceptance rates simultaneously. This isn't a contradiction — structured presentation doesn't mean "sell harder." It means separating the clinical conversation (what needs to happen and why) from the financial conversation (how to make it work within the patient's budget and timeline), and ensuring both conversations happen with the right person at the right time.

When the doctor presents clinical findings and treatment recommendations without discussing cost, and a trained financial coordinator then works with the patient on payment structure, sequencing, and financing — the acceptance rate improves because neither conversation contaminates the other. The patient hears the clinical recommendation from a trusted clinical authority. They hear the financial solution from someone trained to find creative answers, not from the doctor who is cognitively burdened by clinical complexity.

The Unscheduled Treatment Pool

The unaccepted treatment doesn't disappear from the practice's production potential. It sits in the patient base as deferred, unscheduled production. PDA tracks this pool of identified but unconverted treatment as one of the most valuable metrics in practice intelligence — because it represents the exact dollar amount of growth runway available without a single new patient.

The Funnel Axiom

Founders obsess over top-of-funnel marketing, but institutional buyers audit the middle of the funnel. If your case acceptance is 50%, doubling your new patients just doubles your unclosed treatment. Fix the conversion, then pour the gas.

This reframes the entire marketing ROI conversation. The practice spending $15K/month on marketing to generate 40 new patients — but converting only 50% of treatment presented — is investing in patient volume without the conversion infrastructure to monetize it. Every new patient represents a marketing cost and a clinical time investment. If half the treatment identified for those patients goes unscheduled, the effective cost-per-converted-patient doubles.

The highest-ROI investment for most practices is not more new patients — it's closing the treatment already diagnosed and sitting in the patient base. A practice with 500 active patients carrying unscheduled treatment averaging $2,400 per patient has $1.2M in identified, capturable production that requires zero marketing spend to access.

The Valuation Impact

Institutional buyers evaluate case acceptance through the exit lens: is the practice's revenue base maxed out, or does it have embedded growth runway?

A practice converting at 50% has millions in identifiable, capturable production already diagnosed and sitting in the patient base. For a buyer, that is a growth asset, not a weakness — if the buyer believes the system exists to close the gap. Demonstrating that you've already begun closing it — with documented process changes, a structured financing program, trained financial coordinators, and trending case acceptance data showing improvement — is the institutional signal that the growth runway is real and capturable.

Without that documentation, the unconverted treatment is just potential. Every buyer has seen practices with "huge upside" where the upside required the buyer to build systems the seller never bothered to create. That potential gets discounted heavily. But a practice that has already identified the gap, built the system, and can show 12-18 months of improving conversion data has proven the thesis — and proven growth commands premium multiples.